頁籤選單縮合
題 名 | Higher Levels of Soluble Fas Ligand and Transforming Growth Factor-Β after Omalizumab Treatment: A Case Report |
---|---|
作 者 | Kao, Shu-ling; Yu, Hong-ren; Kuo, Ho-chang; Tsui, Ka-yin; Wu, Chih-chiang; Chang, Ling-sai; Liang, Chi-di; Chung, Yu-hsiu; Yang, Kuender D.; | 書刊名 | Journal of Microbiology, Immunology and Infection |
卷 期 | 45:1 2012.02[民101.02] |
頁 次 | 頁69-71 |
分類號 | 418.26 |
關鍵詞 | Asthma; Omalizumab; Soluble FasL; Th1; Th2; |
語 文 | 英文(English) |
英文摘要 | A skewed T-helper (Th)1/Th2 immune response is considered to be the major cause of allergic disorders. Overproduction of Th2 cytokines, which promote recruitment and activation of mast cells and eosinophils, plays a key part in the pathogenesis of allergic asthma. The mechanisms by which omalizumab is effective in asthma treatment are not yet fully understood. A 16-yearold girl who was experiencing frequent asthma attacks in spite of daily administration of budesonide (640 mg) and montelukast (10 mg) was given omalizumab (375 mg) at intervals of 2 weeks, to prevent a visit to the emergency room. Plasma levels of Th1 cytokines [interferon (IFN)-g and interleukin (IL)-12p70], Th2 cytokines (IL-4 and IL-13), other proinflammatory and regulatory cytokines [IL-6, IL-10, IL-17, tumor necrosis factor (TNF)-a, and transforming growth factor (TGF)-b], chemokines [monocyte chemotactic protein (MCP)-1, chemokine ligand (CCL) 7, and CCL17], and soluble Fas ligand (sFasL) were measured before treatment and after treatment for 8 weeks. She showed a good clinical response to omalizumab: her lung function parameters improved and the use of b2-agonist decreased. No emergency room visits were required after omalizumab treatment for 8 weeks. Plasma levels of sFasL and TGF-b showed obvious increases after omalizumab therapy. IL-12p70 levels were decreased as compared to the corresponding baseline levels. These findings suggest that the effects of omalizumab in asthma treatment are not restricted to the regulation of the skewed Th1/Th2 cytokine immune response, and sFasL-mediated apoptosis and regulatory T-cell (Treg)-mediated TGF-b seem to have important roles in the therapeutic effects of omalizumab. |
本系統中英文摘要資訊取自各篇刊載內容。